2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1439

Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies
Abstract Number: 1440

The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated with Tofacitinib
Abstract Number: 1441

Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Abstract Number: 1442

Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Abstract Number: 1443

Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Abstract Number: 1444

Targeted Therapeutic Delivery to Cartilage with Knottin Proteins
Abstract Number: 1445

Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)
Abstract Number: 1446

Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Abstract Number: 1447

Smoking Reduces Efficacy of Biologics Differently By Target Cytokines in Rheumatoid Arthritis
Abstract Number: 1448

Prospective, Intervention, Multicenter, Non-Inferiority Study of Utility of Therapeutic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases
Abstract Number: 1449

Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Abstract Number: 1450

Influence of Immunogenicity to the First Anti-TNF Therapy on Response to the Second Biologic Agent in RA Patients
Abstract Number: 1451

Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results
Abstract Number: 1452

Handling of Missing Data, Protocol Violation and Performance of Intention-to-Treat Analysis in the Randomized Controlled Trials of Drug Therapy of Rheumatoid Arthritis
Abstract Number: 1453

Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].